The PDL1-PD1 axis converts human T H1 cells into regulatory T cells

Science Translational Medicine

Volumn 3, Issue 111, 2011, Pages

  Amarnath, Shoba ^a   Mangus, Courtney W ^a,b   Wang, James C M ^c   Wei, Fang ^d   He, Alice ^a   Kapoor, Veena ^a   Foley, Jason E ^a   Massey, Paul R ^a   Felizardo, Tania C ^a   Riley, James L ^d   Levine, Bruce L ^d   June, Carl H ^d   Medin, Jeffrey A ^c,e   Fowler, Daniel H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT4 PROTEIN; TRANSCRIPTION FACTOR FOXP3; CD274 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW TUMOR; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CLONAL ANERGY; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PLASTICITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TUMOR CELL; WESTERN BLOTTING; XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD274; CELL DIFFERENTIATION; GRAFT VS HOST DISEASE; HUMANS; LIPOPOLYSACCHARIDES; MICE; MODELS, BIOLOGICAL; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 82655184651     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003130     Document Type: Article

References (50)

1. + patients with renal cell carcinoma or melanoma. J. Exp. Med. 196, 619-628 (2002).
2. S. M. Holland, Interferon gamma, IL-12, IL-12R and STAT-1 immunodeficiency diseases: Disorders of the interface of innate and adaptive immunity. Immunol. Res. 38, 342-346 (2007).
3. L. F. Lu, M. P. Boldin, A. Chaudhry, L. L. Lin, K. D. Taganov, T. Hanada, A. Yoshimura, D. Baltimore, A. Y. Rudensky, Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142, 914-929 (2010).
4. J. Mariotti, J. Foley, K. Ryan, N. Buxhoeveden, V. Kapoor, S. Amarnath, D. H. Fowler, Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. Blood 112, 4765-4775 (2008).
5. h2 T cells to express Fas ligand and to undergo activation-induced cell death. Int. Immunol. 6, 1545-1553 (1994).
6. + T cells. Science 327, 1098-1102 (2010).
7. pos regulatory T cells differentiate into IL-17-producing cells. Blood 112, 2340-2352 (2008).
8. X. O. Yang, R. Nurieva, G. J. Martinez, H. S. Kang, Y. Chung, B. P. Pappu, B. Shah, S. H. Chang, K. S. Schluns, S. S. Watowich, X. H. Feng, A. M. Jetten, C. Dong, Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29, 44-56 (2008).
9. R. Mukasa, A. Balasubramani, Y. K. Lee, S. K. Whitley, B. T. Weaver, Y. Shibata, G. E. Crawford, R. D. Hatton, C. T. Weaver, Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. Immunity 32, 616-627 (2010).
10. A. Sher, D. Fiorentino, P. Caspar, E. Pearce, T. Mosmann, Production of IL-10 by CD4+ T lymphocytes correlates with down-regulation of Th1 cytokine synthesis in helminth infection. J. Immunol. 147, 2713-2716 (1991).
11. D. F. Fiorentino, M. W. Bond, T. R. Mosmann, Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170, 2081-2095 (1989).
12. A. C. Mullen, F. A. High, A. S. Hutchins, H. W. Lee, A. V. Villarino, D. M. Livingston, A. L. Kung, N. Cereb, T. P. Yao, S. Y. Yang, S. L. Reiner, Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 292, 1907-1910 (2001).
13. A. A. Lighvani, D. M. Frucht, D. Jankovic, H. Yamane, J. Aliberti, B. D. Hissong, B. V. Nguyen, M. Gadina, A. Sher, W. E. Paul, J. J. O'Shea, T-bet is rapidly induced by interferon-g in lymphoid and myeloid cells. Proc. Natl. Acad. Sci. U.S.A. 98, 15137-15142 (2001).
14. + T cells. Nat. Immunol. 3, 549-557 (2002).
15. L. M. Francisco, P. T. Sage, A. H. Sharpe, The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219-242 (2010).
16. Y. Ohigashi, M. Sho, Y. Yamada, Y. Tsurui, K. Hamada, N. Ikeda, T. Mizuno, R. Yoriki, H. Kashizuka, K. Yane, F. Tsushima, N. Otsuki, H. Yagita, M. Azuma, Y. Nakajima, Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11, 2947-2953 (2005).
17. S.N. Mueller, V. K. Vanguri, S. J. Ha, E. E.West,M. E. Keir, J. N. Glickman, A. H. Sharpe, R. Ahmed, PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J. Clin. Invest. 120, 2508-2515 (2010).
18. B. R. Blazar, B. M. Carreno, A. Panoskaltsis-Mortari, L. Carter, Y. Iwai, H. Yagita, H. Nishimura, P. A. Taylor, Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-g-dependent mechanism. J. Immunol. 171, 1272-1277 (2003).
19. I. Lee, L. Wang, A. D. Wells, Q. Ye, R. Han, M. E. Dorf, W. A. Kuziel, B. J. Rollins, L. Chen, W. W. Hancock, Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1- dependent mechanism. J. Immunol. 171, 6929-6935 (2003).
20. J. M. Chemnitz, R. V. Parry, K. E. Nichols, C. H. June, J. L. Riley, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945-954 (2004).
21. B. T. Fife, K. E. Pauken, T. N. Eagar, T. Obu, J. Wu, Q. Tang, M. Azuma, M. F. Krummel, J. A. Bluestone, Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCRinduced stop signal. Nat. Immunol. 10, 1185-1192 (2009).
22. + Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest. 119, 551-564 (2009).
23. C. J. Ma, L. Ni, Y. Zhang, C. L. Zhang, X. Y. Wu, A. N. Atia, P. Thayer, J. P. Moorman, Z. Q. Yao, PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages during chronic hepatitis C virus infection. Immunology 132, 421-431 (2011).
24. M. D. Sharma, B. Baban, P. Chandler, D. Y. Hou, N. Singh, H. Yagita, M. Azuma, B. R. Blazar, A. L. Mellor, D. H. Munn, Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117, 2570-2582 (2007).
25. S. Amarnath, C. M. Costanzo, J. Mariotti, J. L. Ullman, W. G. Telford, V. Kapoor, J. L. Riley, B. L. Levine, C. H. June, T. Fong, N. L. Warner, D. H. Fowler, Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol. 8, e1000302 (2010).
26. L. M. Francisco, V. H. Salinas, K. E. Brown, V. K. Vanguri, G. J. Freeman, V. K. Kuchroo, A. H. Sharpe, PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015-3029 (2009).
27. T. Sato, A. Neschadim, M. Konrad, D. H. Fowler, A. Lavie, J. A. Medin, Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol. Ther. 15, 962-970 (2007).
28. S. Amarnath, F. A. Flomerfelt, C. M. Costanzo, J. E. Foley, J. Mariotti, D. M. Konecki, A. Gangopadhyay, M. Eckhaus, S. Wong, B. L. Levine, C. H. June, D. H. Fowler, Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy 6, 523-541 (2010).
29. M. J. Butte, M. E. Keir, T. B. Phamduy, A. H. Sharpe, G. J. Freeman, Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111-122 (2007).
30. Y. Latchman, C. R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Y. Iwai, A. J. Long, J. A. Brown, R. Nunes, E. A. Greenfield, K. Bourque, V. A. Boussiotis, L. L. Carter, B. M. Carreno, N. Malenkovich, H. Nishimura, T. Okazaki, T. Honjo, A. H. Sharpe, G. J. Freeman, PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261-268 (2001).
31. L. Chen, S. S. Sung, M. L. Yip, H. R. Lawrence, Y. Ren, W. C. Guida, S. M. Sebti, N. J. Lawrence, J. Wu, Discovery of a novel Shp2 protein tyrosine phosphatase inhibitor. Mol. Pharmacol. 70, 562-570 (2006).
32. M. Song, J. E. Park, S. G. Park, D. H. Lee, H. K. Choi, B. C. Park, S. E. Ryu, J. H. Kim, S. Cho, NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem. Biophys. Res. Commun. 381, 491-495 (2009).
33. T. Ohtani, K. Ishihara, T. Atsumi, K. Nishida, Y. Kaneko, T. Miyata, S. Itoh, M. Narimatsu, H. Maeda, T. Fukada, M. Itoh, H. Okano, M. Hibi, T. Hirano, Dissection of signaling cascades through gp130 in vivo: Reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 12, 95-105 (2000).
34. D. Caretto, S. D. Katzman, A. V. Villarino, E. Gallo, A. K. Abbas, Cutting edge: The Th1 response inhibits the generation of peripheral regulatory T cells. J. Immunol. 184, 30-34 (2010).
35. + T cell function. Jpn. J. Cancer Res. 84, 315-325 (1993).
36. J. G. Egen, M. S. Kuhns, J. P. Allison, CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3, 611-618 (2002).
37. + cell subset with combined Th2 and Th1 cell functions. Immunity 32, 116-128 (2010).
38. X. Chen, R. Das, R. Komorowski, A. Beres, M. J. Hessner, M. Mihara, W. R. Drobyski, Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 114, 891-900 (2009).
39. D. Bending, H. De La Peña, M. Veldhoen, J. M. Phillips, C. Uyttenhove, B. Stockinger, A. Cooke, Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J. Clin. Invest. 119, 565-572 (2009).
40. N. Martin-Orozco, Y. Chung, S. H. Chang, Y. H. Wang, C. Dong, Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur. J. Immunol. 39, 216-224 (2009).
41. Y. K. Lee, H. Turner, C. L. Maynard, J. R. Oliver, D. Chen, C. O. Elson, C. T. Weaver, Late developmental plasticity in the T helper 17 lineage. Immunity 30, 92-107 (2009).
42. E. G. Schulz, L. Mariani, A. Radbruch, T. Höfer, Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-γ and interleukin-12. Immunity 30, 673-683 (2009).
43. M. Gobert, I. Treilleux, N. Bendriss-Vermare, T. Bachelot, S. Goddard-Leon, V. Arfi, C. Biota, A. C. Doffin, I. Durand, D. Olive, S. Perez, N. Pasqual, C. Faure, I. Ray-Coquard, A. Puisieux, C. Caux, J. Y. Blay, C. Ménétrier-Caux, Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 69, 2000-2009 (2009).
44. J. Kline, T. F. Gajewski, Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr. Opin. Investig. Drugs 11, 1354-1359 (2010).
45. P. F. Robbins, R. A. Morgan, S. A. Feldman, J. C. Yang, R. M. Sherry, M. E. Dudley, J. R. Wunderlich, A. V. Nahvi, L. J. Helman, C. L. Mackall, U. S. Kammula, M. S. Hughes, N. P. Restifo, M. Raffeld, C. C. Lee, C. L. Levy, Y. F. Li, M. El-Gamil, S. L. Schwarz, C. Laurencot, S. A. Rosenberg, Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924 (2011).
46. + T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70, 6725-6734 (2010).
47. J. L. Riley, C. H. June, B. R. Blazar, Human T regulatory cell therapy: Take a billion or so and call me in the morning. Immunity 30, 656-665 (2009).
48. M. Yoshimitsu, T. Sato, K. Tao, J. S. Walia, V. I. Rasaiah, G. T. Sleep, G. J. Murray, A. G. Poeppl, J. Underwood, L. West, R. O. Brady, J. A. Medin, Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc. Natl. Acad. Sci. U.S.A. 101, 16909-16914 (2004).
49. T. G. Abrahamsen, C. S. Carter, E. J. Read, M. Rubin, H. G. Goetzman, E. F. Lizzio, Y. L. Lee, M. Hanson, P. A. Pizzo, T. Hoffman, Stimulatory effect of counterflow centrifugal elutriation in large-scale separation of peripheral blood monocytes can be reversed by storing the cells at 37° C. J. Clin. Apher. 6, 48-53 (1991).
50. null mice. Exp. Hematol. 35, 1823-1838 (2007).